Licensed preventive vaccines against various infectious diseases have been designed as (1) attenuated pathogens (e.g., chickenpox, mumps-measles-rubella, yellow fever, shingles [varicella-zoster], and rotavirus), (2) inactivated pathogens (e.g., diphtheria-pertussis-tetanus, trivalent influenza, Japanese encephalitis, meningococcal vaccine, typhoid fever, poliomyelitis, and hepatitis A), and (3) recombinant proteins (e.g., hepatitis B, type B Hemophilus influenzae, pneumococcal vaccine, and HPV prophylactic vaccines).
PapiVax Biotech, Inc. (PBI) is a biotechnology company that intends to become a global leader in immunotherapy for chronic viral infections and related cancers through application of our state-of-the-art immunotherapy platforms and expertise, first to treat human papillomavirus (HPV) infections and their related cancers, and then to expand their application against other chronic virus infection-related human cancers, such as those driven by HBV and EBV.